GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland)
Phase of Trial: Phase II/III
Latest Information Update: 22 Jul 2019
Price : $35 *
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Stroke; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms GLORIA-AF
- Sponsors Boehringer Ingelheim
- 18 Jul 2019 Status changed from active, no longer recruiting to completed.
- 31 Oct 2018 Planned primary completion date changed from 14 Jan 2020 to 31 Dec 2019.
- 20 Aug 2018 According to a Boehringer Ingelheim media release, data will be presented at the at the upcoming ESC Congress 2018.